See more : Ningxia Zhongyin Cashmere Co., Ltd. (000982.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Ventyx Biosciences, Inc. (VTYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ventyx Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Foresight Autonomous Holdings Ltd. (FRSX) Income Statement Analysis – Financial Results
- Community Financial Group, Inc. (Spokane, WA) (CFGW) Income Statement Analysis – Financial Results
- Entrée Resources Ltd. (ERLFF) Income Statement Analysis – Financial Results
- Whispir Limited (WHSPF) Income Statement Analysis – Financial Results
- Air New Zealand Limited (AIZ.AX) Income Statement Analysis – Financial Results
Ventyx Biosciences, Inc. (VTYX)
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 941.00K | 470.00K | 30.00K | 0.00 | 0.00 |
| Gross Profit | -941.00K | -470.00K | -30.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 175.77M | 87.74M | 58.48M | 6.37M | 3.55M |
| General & Administrative | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Other Expenses | 0.00 | 41.00K | -5.45M | -1.00K | -1.00K |
| Operating Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Cost & Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Interest Income | 15.07M | 4.67M | 78.00K | 358.00 | 146.00 |
| Interest Expense | 0.00 | 0.00 | 99.00K | 358.00K | 146.00K |
| Depreciation & Amortization | 158.00K | 470.00K | 30.00K | 7.05M | 4.18M |
| EBITDA | -207.84M | -107.96M | -67.12M | 0.00 | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.99M | -113.14M | -67.15M | -7.05M | -4.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.03M | 4.71M | -16.60M | -21.12M | -147.00K |
| Income Before Tax | -192.96M | -108.43M | -83.75M | -28.17M | -4.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -470.00K | -5.38M | 358.00K | 146.00K |
| Net Income | -192.96M | -107.96M | -78.37M | -28.53M | -4.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| EPS Diluted | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| Weighted Avg Shares Out | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
| Weighted Avg Shares Out (Dil) | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Lawsuit - VTYX
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
Contact Levi & Korsinsky by April 30, 2024 Deadline to Join Class Action Against Ventyx Biosciences, Inc.(VTYX)
Contact Levi & Korsinsky by April 30, 2024 Deadline to Join Class Action Against Ventyx Biosciences, Inc.(VTYX)
Source: https://incomestatements.info
Category: Stock Reports